Icon AI Stock Analysis
Want to see ICLR full AI Analyst Report?
Icon (ICLR) AI Stock Analysis
Icon
(NASDAQ:ICLR)
ICLR’s score is primarily supported by solid financial resilience (strong cash generation and manageable leverage) and constructive earnings-call indicators (record bookings and maintained margin outlook). This is offset by weak recent top-line performance and compressed profitability versus prior years, while a strong technical uptrend is tempered by overbought momentum signals and a high P/E valuation with no dividend support.
Icon (ICLR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $14.34B
- Dividend Yield
- ―
- Average Volume (3M)
- 976.88K
- Price to Earnings (P/E)
- 32.8
- Beta (1Y)
- 0.88
- Revenue Growth
- 0.67%
- EPS Growth
- 43.70%
- Country
- US
- Employees
- 40,200
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Diagnostics & Research
Icon Business Overview & Revenue Model
Company Description
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, ma...
How the Company Makes Money
ICON primarily makes money by providing fee-based outsourced research and development services to life sciences sponsors. Its revenue model is largely services-driven and tied to sponsor contracts for clinical development and related activities. Key...
Icon Earnings Call Summary
The call was strongly positive overall. Commercial momentum, record net bookings, sustained book-to-bill performance, margin expansion, cost discipline, cash generation, technology productivity gains, and constructive demand outweighed the year-over-year revenue decline, pass-through volatility, foreign exchange headwind, and expected fourth-quarter SG&A increase.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
For 2026, updated full year guidance reflects higher pass through activity, supporting an increase in the revenue outlook to the high end of the prior range, or about $150 million at the midpoint from where it was before; full year EBITDA margin is expected to be somewhere in the region of 16% to 16.5%, the adjusted effective tax rate approximately 17%, and Q4 SG&A should increase. Pass throughs are currently somewhere in the low thirties, approaching 1 third of revenues approximately, with somewhere in or around that range a reasonable place to think about for next year. The company is not guiding today for 2027, but said it is certainly viable to think about mid single digit revenue expansion next year and maybe higher single digit expansion on earnings, with good execution, meaningful earnings progression, and even at the midpoint another dozen cents or so of earnings expansion quarter over quarter.
Icon Financial Statement Overview
Summary
Solid cash generation and a sturdy, improving balance sheet support the profile (TTM operating cash flow ~$1.54B; debt-to-equity ~0.37). However, the income statement is pressured by a sharp TTM revenue decline (~-21.9%) and margin compression versus 2023–2024, keeping profitability and returns only moderate (TTM net margin ~4.0%; ROE ~4.9%).
Income Statement
62PositiveBalance Sheet
74PositiveCash Flow
68Positive| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.23B | 8.25B | 8.28B | 8.12B | 7.74B | 5.48B |
| Gross Profit | 1.74B | 2.18B | 2.44B | 2.40B | 2.21B | 1.51B |
| EBITDA | 1.37B | 823.57M | 1.56B | 1.52B | 1.37B | 694.09M |
| Net Income | 448.66M | 229.34M | 791.47M | 612.34M | 505.30M | 153.19M |
Balance Sheet | ||||||
| Total Assets | 16.24B | 16.27B | 16.88B | 16.99B | 17.19B | 17.39B |
| Cash, Cash Equivalents and Short-Term Investments | 808.98M | 647.29M | 538.78M | 380.06M | 290.48M | 753.92M |
| Total Debt | 3.51B | 3.56B | 3.60B | 3.94B | 4.83B | 5.65B |
| Total Liabilities | 7.12B | 7.08B | 7.35B | 7.75B | 8.69B | 9.32B |
| Stockholders Equity | 9.13B | 9.19B | 9.52B | 9.24B | 8.50B | 8.07B |
Cash Flow | ||||||
| Free Cash Flow | 1.28B | 861.99M | 1.12B | 1.02B | 421.15M | 735.39M |
| Operating Cash Flow | 1.54B | 1.04B | 1.29B | 1.16B | 563.32M | 829.14M |
| Investing Cash Flow | -346.81M | -187.53M | -266.79M | -226.65M | -145.87M | -6.02B |
| Financing Cash Flow | -926.26M | -771.26M | -837.18M | -844.04M | -864.17M | 5.11B |
Icon Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ICLR, the sentiment is Positive. The current price of 191.40 is below the 20-day moving average (MA) of 197.74, above the 50-day MA of 179.55, and above the 200-day MA of 146.75, indicating a neutral trend. The MACD of 5.86 indicates Positive momentum. The RSI at 49.38 is Neutral, neither overbought nor oversold. The STOCH value of 18.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ICLR.
Icon Risk Analysis
Icon disclosed 66 risk factors in its most recent earnings report. Icon reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksIcon Peers Comparison
Overall Rating
MEDP84Outperform
TMO76.9Outperform
LH75Outperform
IQV74Outperform
ICLR69Neutral
CRL62Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 84Outperform | $18.13B | 35.47 | 99.76% | ― | 20.35% | 25.24% | |
| 77Outperform | $256.15B | 36.40 | 13.31% | 0.27% | 8.27% | 9.59% | |
| 75Outperform | $30.24B | 30.30 | 11.54% | 0.77% | 6.02% | 19.63% | |
| 74Outperform | $43.63B | 31.85 | 21.82% | ― | 8.88% | 13.11% | |
| 69Neutral | $14.34B | 32.76 | 4.85% | ― | 0.67% | 43.70% | |
| 62Neutral | $16.08B | 328.75 | 1.32% | ― | -1.16% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| ICLR | Icon Plc | 191.40 | 30.38 | 18.87% | |
| CRL | Charles River Laboratories Intl | 335.52 | 172.99 | 106.44% | |
| LH | Labcorp Holdings Inc. | 372.46 | 115.25 | 44.81% | |
| TMO | Thermo Fisher Scientific | 691.33 | 117.32 | 20.44% | |
| IQV | IQVIA Holdings | 264.73 | 47.45 | 21.84% | |
| MEDP | Medpace Holdings Inc | 648.20 | 58.02 | 9.83% |
Icon Corporate Events
ICON Announces Participation in Jefferies and Evercore Healthcare Conferences
ICON plc is a clinical research organization serving pharmaceutical, biotechnology, medical-device, government and public-health organizations worldwide. It provides integrated consulting, clinical development, commercialization and post-marketing so...
ICON Restructures Debt, Expands Buybacks and Extends Option Plans
In July 2026, ICON drew down its $500 million Bridge Secured Credit Facility to repay maturing 2.875% Senior Secured Notes, then fully repaid the bridge facility by August 17, 2026, simplifying near-term debt obligations. On August 13, 2026, a wholly...
ICON plc Posts Strong Q3 2026 Bookings, Refinances Debt With $2.15 Billion Bond
ICON plc reported third‑quarter 2026 results on October 27, 2026, highlighting strong commercial momentum with net business wins of $3.15 billion, a book‑to‑bill of 1.56x and backlog rising to $24.5 billion. Revenue for the quarter was $2.02 billion,...
ICON plc Sets Dates for Third-Quarter 2026 Earnings Release and Call
ICON plc announced on October 8, 2026 that it will publish its financial results for the third quarter of 2026 after U.S. market close on Tuesday, October 27, 2026. The company will host a conference call and webcast the following day, Wednesday, Oct...
ICON Files September 2026 Form 6-K With Unaudited Interim Results
ICON plc, a Dublin-headquartered clinical research organization serving global pharmaceutical and biotech clients, has filed its latest report as a foreign private issuer with the U.S. Securities and Exchange Commission. The company continues to prov...
ICON Showcases 2025 ESG and Innovation Gains in Latest ICON Cares Report
ICON plc, headquartered in Dublin, Ireland, is a global clinical research organisation that delivers consulting, clinical development, commercialisation and post‑marketing services to pharmaceutical, biotechnology, medical device, government and publ...
ICON plc Raises $2.15 Billion in Senior Notes to Refinance Secured Debt
On August 13, 2026, ICON Investments Six DAC, a wholly owned subsidiary of ICON plc, issued $2.15 billion of senior unsecured notes in three tranches due 2029, 2031 and 2036, all guaranteed by ICON. The notes were placed privately with institutional...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 29, 2026
